ArticleJournal of inflammation research2025
Bergenin Alleviates Myocardial Ischemia/Reperfusion Injury via Regulating SIRT1 Through Ferroptosis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- SIRT1 in Cardiac Diseases: Molecular Mechanisms, Therapeutic Potential, and Future Directions.International journal of molecular sciences · 2026Review
- Time-Stable Ferroptosis-Related Candidate Genes in Myocardial Ischemia/Reperfusion Injury Identified by Multi-Time-Point Transcriptomic Analysis: Prioritization of NCF2 Through Public Datasets and AC16 Cell Validation.Journal of inflammation research · 2026Article
- Acupuncture modulates extracellular vesicle-miRNA-HMOX1 axis to inhibit ferroptosis in polycystic ovary syndrome: integrating machine learning,Frontiers in endocrinology · 2026Article
- Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosisWorld journal of diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the protective effect of bergenin on myocardial ischemia/reperfusion (I/R) injury and to elucidate its underlying mechanism. Methods: The in vivo model of myocardial I/R injury was established by transient ligation of the left anterior descending coronary artery in Sprague-Dawley rats, which were divided into sham, I/R, I/R+bergenin, and I/R+bergenin+erastin (an agonist of ferroptosis) groups.After the model was established, the rats underwent echocardiography to assess the cardiac function. Hematoxylin and eosin (HE) staining and Masson's trichrome staining were performed to evaluate the cardiac pathological damage. Malondialdehyde (MDA), reactive oxygen species (ROS), glutathione (GSH) and iron levels were measured to determine the ferroptosis level. Western blotting was used to detect the expression of related proteins. Next, H9C2 cells were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) to mimic the in vitro model of myocardial I/R injury. EX527, a SIRT1 inhibitor, was used to further explore the role of SIRT1 in the myocardial protection of bergenin. In this part of the experiment, H9C2 cells were divided into four groups: control, OGD/R, OGD/R+bergenin, and OGD/R+bergenin+EX527. Results: In vivo experiments, we found that the I/R group showed obvious myocardial pathological damage, oxidative stress and ferroptosis, while the bergenin pretreatment group reversed the above myocardial injury, but this protective effect was inhibited by the ferroptosis inducer erastin. In vitro experiments, compared with the OGD/R group, the bergenin group reduced the oxidative stress level, mitochondrial dysfunction and ferroptosis of H9C2 cells. We found that the protective effect of bergenin on the myocardium was abrogated by EX527. Moreover, Western blotting showed that bergenin activated SIRT1, and increased the phosphorylation of AMPK and the expression level of PGC-1α. Conclusion: Bergenin exerted a protective effect on the myocardium by modulating the ferroptosis process during myocardial I/R injury through the SIRT1/AMPK/PGC-1α pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.